Rosemont, a liquid pharmaceutical company based in Leeds, has been acquired from its listed US owner by London-based private equity firm, Inflexion, for £156 million.
Rosemont’s portfolio of over 130 oral liquid medicines includes over 70 licensed products which are sold into the UK as well as the US, Continental Europe and the Middle East.
The business benefits from strong R&D and innovation, and has built a track record of successful new product launches.
With substantial experience in successfully executing carve-outs, Inflexion will draw upon its healthcare expertise to establish Rosemont as a standalone business and invest further in innovation and new product development. Inflexion will also support the geographical expansion of the business.
“We’re extremely pleased to be able to announce this exciting new chapter for Rosemont. As a very well established and respected supplier in the industry, we look forward to working with Inflexion and drawing on their relevant experience in our sector to continue to invest in the business and expand our quality product range,” said Rosemont CEO, Howard Taylor.
Simon Turner Managing Partner of Inflexion said: “We are delighted to be partnering with Rosemont on their journey to become a standalone business.
“Our experience in helping businesses to become independent combined with our success in growing healthcare businesses make us confident our partnership will be an excellent foundation for further innovation and new product development.”